Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes : Individual effects of treatment. / Zobel, Emilie Hein; von Scholten, Bernt Johan; Lindhardt, Morten; Persson, Frederik; Hansen, Tine Willum; Rossing, Peter.

I: Journal of Diabetes and its Complications, Bind 31, Nr. 1, 01.2017, s. 162-168.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Zobel, EH, von Scholten, BJ, Lindhardt, M, Persson, F, Hansen, TW & Rossing, P 2017, 'Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment', Journal of Diabetes and its Complications, bind 31, nr. 1, s. 162-168. https://doi.org/10.1016/j.jdiacomp.2016.09.016

APA

Zobel, E. H., von Scholten, B. J., Lindhardt, M., Persson, F., Hansen, T. W., & Rossing, P. (2017). Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. Journal of Diabetes and its Complications, 31(1), 162-168. https://doi.org/10.1016/j.jdiacomp.2016.09.016

CBE

Zobel EH, von Scholten BJ, Lindhardt M, Persson F, Hansen TW, Rossing P. 2017. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. Journal of Diabetes and its Complications. 31(1):162-168. https://doi.org/10.1016/j.jdiacomp.2016.09.016

MLA

Vancouver

Zobel EH, von Scholten BJ, Lindhardt M, Persson F, Hansen TW, Rossing P. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. Journal of Diabetes and its Complications. 2017 jan;31(1):162-168. https://doi.org/10.1016/j.jdiacomp.2016.09.016

Author

Zobel, Emilie Hein ; von Scholten, Bernt Johan ; Lindhardt, Morten ; Persson, Frederik ; Hansen, Tine Willum ; Rossing, Peter. / Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes : Individual effects of treatment. I: Journal of Diabetes and its Complications. 2017 ; Bind 31, Nr. 1. s. 162-168.

Bibtex

@article{167002223f5f482f95905a4a93d78780,
title = "Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment",
abstract = "Aims/hypothesis Management of diabetic nephropathy includes reduction of albuminuria, blood pressure and weight. The GLP-1 receptor agonist liraglutide may possess these pleiotropic effects in addition to the glucose lowering effect. We aimed to elucidate the individual liraglutide treatment response by determining if high responders (highest reduction) in each risk factor also had high response in other renal risk factors (cross-dependency). Methods Open-label study: 31 type 2 diabetics treated with liraglutide for 7 weeks. After 3 weeks washout 23 re-started treatment and were followed for 1 year. HbA1c, weight, systolic blood pressure (SBP), urinary albumin excretion rate (UAER) and mGFR (51Cr-EDTA) were evaluated. Changes in high (Q4) vs. low responders (Q1–Q3) were compared for each renal risk factor. The effects of treatment/off treatment/re-treatment (off–on/off–on effect) were evaluated to account for random effects. Results After 7 weeks HbA1c was reduced 6(95% CI: 3;9) mmol/mol, weight 2.5(1.8;3.2) kg, SBP 4(− 1;9) mmHg, UAER 30(12;44)% and mGFR 11(7;14) ml/min per 1.73 m2. mGFR high responders had a significant reduction in weight compared to low responders (4.3 vs. 1.9 kg; p = 0.002). SBP high responders had a tendency of a higher reduction in UAER compared to low responders (47 vs. 23%, p = 0.14). No cross-dependency was observed in any of the other renal risk factors (p ≥ 0.16). Treatment response did not differ after 7 weeks and 1 year (p ≥ 0.12). Conclusions/interpretation Liraglutide possesses pleiotropic effects on renal risk factors. On patient level, effect on the individual risk factor cannot be anticipated based on response in other risk factors. Response when re-starting treatment did not differ, indicating that our primary findings were not random.",
keywords = "Diabetic nephropathy, Glomerular filtration rate, GLP-1, Liraglutide, Type 2 diabetes",
author = "Zobel, {Emilie Hein} and {von Scholten}, {Bernt Johan} and Morten Lindhardt and Frederik Persson and Hansen, {Tine Willum} and Peter Rossing",
year = "2017",
month = jan,
doi = "10.1016/j.jdiacomp.2016.09.016",
language = "English",
volume = "31",
pages = "162--168",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes

T2 - Individual effects of treatment

AU - Zobel, Emilie Hein

AU - von Scholten, Bernt Johan

AU - Lindhardt, Morten

AU - Persson, Frederik

AU - Hansen, Tine Willum

AU - Rossing, Peter

PY - 2017/1

Y1 - 2017/1

N2 - Aims/hypothesis Management of diabetic nephropathy includes reduction of albuminuria, blood pressure and weight. The GLP-1 receptor agonist liraglutide may possess these pleiotropic effects in addition to the glucose lowering effect. We aimed to elucidate the individual liraglutide treatment response by determining if high responders (highest reduction) in each risk factor also had high response in other renal risk factors (cross-dependency). Methods Open-label study: 31 type 2 diabetics treated with liraglutide for 7 weeks. After 3 weeks washout 23 re-started treatment and were followed for 1 year. HbA1c, weight, systolic blood pressure (SBP), urinary albumin excretion rate (UAER) and mGFR (51Cr-EDTA) were evaluated. Changes in high (Q4) vs. low responders (Q1–Q3) were compared for each renal risk factor. The effects of treatment/off treatment/re-treatment (off–on/off–on effect) were evaluated to account for random effects. Results After 7 weeks HbA1c was reduced 6(95% CI: 3;9) mmol/mol, weight 2.5(1.8;3.2) kg, SBP 4(− 1;9) mmHg, UAER 30(12;44)% and mGFR 11(7;14) ml/min per 1.73 m2. mGFR high responders had a significant reduction in weight compared to low responders (4.3 vs. 1.9 kg; p = 0.002). SBP high responders had a tendency of a higher reduction in UAER compared to low responders (47 vs. 23%, p = 0.14). No cross-dependency was observed in any of the other renal risk factors (p ≥ 0.16). Treatment response did not differ after 7 weeks and 1 year (p ≥ 0.12). Conclusions/interpretation Liraglutide possesses pleiotropic effects on renal risk factors. On patient level, effect on the individual risk factor cannot be anticipated based on response in other risk factors. Response when re-starting treatment did not differ, indicating that our primary findings were not random.

AB - Aims/hypothesis Management of diabetic nephropathy includes reduction of albuminuria, blood pressure and weight. The GLP-1 receptor agonist liraglutide may possess these pleiotropic effects in addition to the glucose lowering effect. We aimed to elucidate the individual liraglutide treatment response by determining if high responders (highest reduction) in each risk factor also had high response in other renal risk factors (cross-dependency). Methods Open-label study: 31 type 2 diabetics treated with liraglutide for 7 weeks. After 3 weeks washout 23 re-started treatment and were followed for 1 year. HbA1c, weight, systolic blood pressure (SBP), urinary albumin excretion rate (UAER) and mGFR (51Cr-EDTA) were evaluated. Changes in high (Q4) vs. low responders (Q1–Q3) were compared for each renal risk factor. The effects of treatment/off treatment/re-treatment (off–on/off–on effect) were evaluated to account for random effects. Results After 7 weeks HbA1c was reduced 6(95% CI: 3;9) mmol/mol, weight 2.5(1.8;3.2) kg, SBP 4(− 1;9) mmHg, UAER 30(12;44)% and mGFR 11(7;14) ml/min per 1.73 m2. mGFR high responders had a significant reduction in weight compared to low responders (4.3 vs. 1.9 kg; p = 0.002). SBP high responders had a tendency of a higher reduction in UAER compared to low responders (47 vs. 23%, p = 0.14). No cross-dependency was observed in any of the other renal risk factors (p ≥ 0.16). Treatment response did not differ after 7 weeks and 1 year (p ≥ 0.12). Conclusions/interpretation Liraglutide possesses pleiotropic effects on renal risk factors. On patient level, effect on the individual risk factor cannot be anticipated based on response in other risk factors. Response when re-starting treatment did not differ, indicating that our primary findings were not random.

KW - Diabetic nephropathy

KW - Glomerular filtration rate

KW - GLP-1

KW - Liraglutide

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85005952250&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2016.09.016

DO - 10.1016/j.jdiacomp.2016.09.016

M3 - Journal article

C2 - 27769801

AN - SCOPUS:85005952250

VL - 31

SP - 162

EP - 168

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 1

ER -